Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft.

ABSTRACT: Nimotuzumab is a humanized anti-epidermal growth factor receptor I (EGFR) monoclonal antibody. We have developed antibody drug conjugates (ADCs) with nimotuzumab conjugated to PEGylated-maytansine (PEG₆-DM1). We generated conjugates with low (nimotuzumab-PEG₆-DM1-Low: DAR = 3.5) and high (nimotuzumab-PEG₆-DM1-High: DAR = 7.3) drug to antibody ratios (DAR). Quality control was performed using UV spectrophotometry, size exclusion HPLC, bioanalyzer, biolayer interferometry (BLI), and flow cytometry in EGFR-positive DLD-1, MDA-MB-468 (high density EGFR), and HT-29 (very low EGFR density) cells. Control antibody drug conjugates were developed using a human anti-maltose binding protein (MBP) antibody. BLI showed that the binding of nimotuzumab-PEG₆-DM1

SUBMITTER: Hartimath SV 

PROVIDER: S-EPMC6383682 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature